|
|
|
Insider
Information: |
Robinson Chandler |
Relationship: |
Chief Executive Office... |
City: |
Wilmette |
State: |
IL |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
265,923 |
|
Indirect Shares
|
4,277,940 |
|
|
Direct
Value |
$186,199 |
|
|
Indirect Value
|
$2,995,414 |
|
|
Total
Shares |
4,543,863 |
|
|
Total
Value |
$3,181,613 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Monopar Therapeutics |
MNPR |
Chief Executive Office... |
2024-06-30 |
265,923 |
2024-06-30 |
4,277,940 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
33 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2021-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,724 |
20,727 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2021-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,883 |
26,283 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,941 |
27,914 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,941 |
30,700 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,724 |
36,060 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,941 |
37,674 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2022-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,882 |
60,401 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2022-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,911 |
67,313 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2022-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,912 |
77,148 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,723 |
79,057 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2023-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,039 |
121,394 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2023-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,474 |
135,599 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2023-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,474 |
152,901 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,724 |
151,156 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2024-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,474 |
173,303 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2024-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,476 |
274,607 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2024-05-28 |
4 |
OE |
$0.00 |
$84 |
D/D |
84,000 |
250,131 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2024-01-01 |
4 |
D |
$0.34 |
$792 |
D/D |
(2,327) |
148,829 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2023-12-31 |
4 |
D |
$0.34 |
$2,881 |
D/D |
(8,469) |
144,432 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2022-03-31 |
4 |
D |
$2.55 |
$2,945 |
D/D |
(1,155) |
36,519 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2021-12-31 |
4 |
D |
$3.21 |
$4,378 |
D/D |
(1,364) |
29,336 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2023-09-30 |
4 |
D |
$0.62 |
$4,446 |
D/D |
(7,172) |
128,427 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2024-03-31 |
4 |
D |
$0.68 |
$4,884 |
D/D |
(7,172) |
166,131 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2023-01-01 |
4 |
D |
$2.37 |
$5,515 |
D/D |
(2,327) |
76,730 |
0 |
- |
|
MNPR |
Monopar Therapeutics |
Chief Executive Officer |
|
2021-09-30 |
4 |
D |
$4.87 |
$5,625 |
D/D |
(1,155) |
26,759 |
0 |
- |
|
33 Records found
|
|
Page 1 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|